The following ten projects have been granted funding:
- Joakim Bergström: Untangling of alpha-synuclein at the synapse in dementia diseases
- Anna Erlandsson: The role of astrocytes in development and progression of Alzheimer’s disease
- Greta Hultqvist: Translational blood–brain barrier transporter for immunotherapy and -diagnostics of Alzheimer’s disease
- Martin Ingelsson: Alpha-synuclein and amyloid-β pathology – novel targets for development of immunotherapy and genetherapy against Alzheimer’s disease and related disorders
- Lars Lannfelt: Investigations on the novel “Uppsala” mutation causing a familial form of very early-onset Alzheimer’s disease
- Paul O’Callaghan: Deconstructing the molecular machinery of microglial-mediated neuroinflammation in Alzheimer’s disease
- Dag Sehlin: Enhanced brain delivery of antibodies for effective treatment of Alzheimer’s disease
- Stina Syvänen: Disease progression and treatment effects in Alzheimer’s disease visualised with novel bispecific protein based radioligands
- Gunilla Westermark: Protein aggregation as a molecular link between Alzheimer’s disease and type 2 diabetes
- Anna Cristina Åberg: Walking test for memory assessments.
Facts about dementia:
Dementia is not normal ageing. It is a disease that affects the brain and destroys its ability to think and act logically. Dementia is caused by around 70 different diseases, one of the most common being Alzheimer’s disease.
Today, some 160,000 people in Sweden are diagnosed with dementia. In Sweden, around 70 people are diagnosed with dementia every day. By the year 2050, the number of dementia patients in Sweden is expected to double.